The company maintains a robust pipeline, fortress-like balance sheet, and focus on addressing Multiple System Atrophy (MSA). Theravance has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI, providing diversified revenue streams and reduced development risk.
Cyborg Score Rationale
The company holds $338.8 million in cash as of June 2025, providing a 7.4-year runway at current burn rates without dilution. Revenue diversification from partnerships generated $18.7 million from Viatris in Q2 2025 and $7.5 million in licensing revenue, with disciplined cost management supporting cash preservation.
Top Insights
$338.8 million in cash from GSK milestone payment for TRELEGY royalty interest sale provides substantial runway for pipeline advancement
Viatris partnership and YUPELRI China approval generated $26.2 million in collaborative revenue in Q2 2025, demonstrating diversification
CYPRESS trial progression for Ampreloxetine in MSA represents key catalyst with expanding addressable market
Lean operational structure with 97 full-time employees enables capital efficiency and agile drug development
Named Competitors
LAMA therapies for COPD — Established COPD treatment options